Navigating Giant Cell Arteritis: Diagnosis, Management, and the Road Ahead - Episode 15
The Trial Design and Interim Results From the GCAptAIN Trial
Published on:
This video covers the following questions:
- Secukinumab, an IL‑17A inhibitor, emerged as a promising candidate for GCA based on Phase II data from last year showing 70% sustained remission at week 28 versus 20% with placebo (Venhoff 2023).
- Please share the results of Phase III GCAptAIN trial. How do you interpret these findings? (Novartis Press Release)
